JB Chemicals & Pharmaceuticals Limited — Important, 16-01-2025: Updates

The presentation outlines JB Chemicals & Pharmaceuticals' impressive growth trajectory and strategic initiatives spearheaded by the management team.

**Financial Highlights:** JB Pharma achieved INR 34,840 million in revenue for FY24, marking an 18% CAGR from FY20–24. Operating EBITDA also saw strong growth, with an operating margin consistently exceeding 26%. The company recorded significant domestic market achievements, ranking 16th overall within the Indian pharmaceutical market (IPM), bolstered by 5 brands listed among the top 150.

**Strategic Initiatives and Growth Drivers:** The company is focused on expanding its chronic disease portfolio and has recently acquired multiple key brands to enhance its therapeutic presence in cardiology, nephrology, and pediatrics. Notable acquisitions have propelled its ranking in cardiology from 15th to 8th.

**Market Position and Competitive Advantage:** With a robust go-to-market model and pan-India presence, JB Pharma has improved field force productivity significantly. Its diverse international business also contributes to a strong global footprint, especially in high-demand segments like lozenges and gastrointestinal products.

**Investor Implications:** The outlook for JB Pharma appears positive, with a focus on sustainable growth and enhanced operational efficiency. The strategic emphasis on chronic therapies and international expansion positions the company favorably for continued market share gains and long-term value creation. Investors should watch closely as the company capitalizes on its recent investments and market positioning.